Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Invion's Enterprise Value is $2.97 Mil.
Invion's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.72 Mil. Therefore, Invion's EV-to-OCF for today is -1.73.
The historical rank and industry rank for Invion's EV-to-OCF or its related term are showing as below:
IVIXF'
s EV-to-OCF Range Over the Past 10 Years
Min: -719.69 Med: -10.38 Max: 354.47
Current: -1.65
During the past 13 years, the highest EV-to-OCF of Invion was 354.47. The lowest was -719.69. And the median was -10.38.
IVIXF's EV-to-OCF is ranked better than 73.06% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 10.6
vs IVIXF: -1.65
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-20), Invion's stock price is $0.0369.
Invion's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.090. Therefore, Invion's PE Ratio (TTM) for today is At Loss.
Invion (OTCPK:IVIXF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Invion's share price for today is $0.0369.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Invion's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.090.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Invion EV-to-OCF Related Terms
Invion EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Invion's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Invion's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invion EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Invion's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Invion's EV-to-OCF falls into.
Invion's current Enterprise Value is $2.97 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Invion's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-1.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invion (IVIXF) has a EV-to-OCF of -1.73 as of Jul. 20, 2026. According to the industry distribution chart, Invion ranks #271 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 26.9%.
Is Invion's EV-to-OCF too high?
Invion's current EV-to-OCF is -1.73. Based on the distribution chart, Invion ranks #271 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Invion has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Invion's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Invion ranks #271 out of 1006 companies for EV-to-OCF. This puts Invion in the upper half of its industry. The industry median EV-to-OCF is 10.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.60, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invion's current EV-to-OCF is -1.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invion stock overvalued right now?
Invion (IVIXF) has a current EV-to-OCF of -1.73. The stock's GF Value™ is $0.19, compared to a current price of $0.04 — trading 80.6% below its estimated fair value. The current EV-to-OCF is -1.73. Invion's overall GF Score™ is 16/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Invion (IVIXF), the current EV-to-OCF is -1.73 as of Jul. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Invion (IVIXF) Overvalued in 2026?
Based on GuruFocus' analysis, Invion stock appears to be undervalued.
The current stock price of $0.04 is trading 80.6% below its estimated GF Value™ of $0.19.
Key valuation signals for IVIXF:
EV-to-OCF: -1.73
GF Value™: $0.19 vs. price of $0.04 (80.6% below fair value)
No single metric tells the full story. See the IVIXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Invion Ltd is an Australian clinical-stage pharmaceutical drug development company. It is engaged in the development of PhotoDynamic Therapy (PDT) for cancer treatments called Photosoft, for the treatment of a range of cancers, and infectious diseases. The company produces topical and intravenous products suitable for use in skin cancer and solid tumors, such as ovarian, prostate, and lung cancer. Invion has developed a portfolio of patent protected compounds. Its drug candidate is INV043, a novel photosensitiser which has the potential to work as a therapy and a diagnostic tool.
16GF Score
Get the complete analysis for IVIXF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVIXF has been successfully added to your 
